Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tropifexor and Licogliflozin in NASH
NCT04065841Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 2 trial of tropifexor, licogliflozin in Nonalcoholic steatohepatitis (NASH), sponsored by Novartis. Started Dec 2019; status: terminated.
02
Drugs
tropifexorlicogliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04065841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065841.